Evidence map›Paper›PMID 35092578›Full record

ReviewClinical reviews in allergy & immunology2022

Road Less Traveled: Drug Hypersensitivity to Fluoroquinolones, Vancomycin, Tetracyclines, and Macrolides.

Linda J Zhu, Anne Y Liu, Priscilla H Wong, Anna Chen Arroyo

Open access · greenAbstract readReview
In one paragraph

Review in Clinical reviews in allergy & immunology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
4.5field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 30 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Recent epidemiological and management approaches for cholera in India.Proceedings (Baylor University. Medical Center) · 2026
    Review
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Non-IgE-Mediated Immediate Drug-Induced Hypersensitivity Reactions.The journal of allergy and clinical immunology. In practice · 2024
    Article
  17. Review
  18. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Linda J ZhuDivision of Pulmonary, Allergy & Critical Care Medicine, Department of Medicine, Stanford University School of Medicine, 300 Pasteur Drive, MC 5573, Stanford, CA, 94305, USA. lindazhu@stanford.edu.ORCID http://orcid.org/0000-0001-6246-4300
Anne Y LiuDivision of Pulmonary, Allergy & Critical Care Medicine, Department of Medicine, Stanford University School of Medicine, 300 Pasteur Drive, MC 5573, Stanford, CA, 94305, USA.
Priscilla H WongDivision of Pulmonary, Allergy & Critical Care Medicine, Department of Medicine, Stanford University School of Medicine, 300 Pasteur Drive, MC 5573, Stanford, CA, 94305, USA.
Anna Chen ArroyoDivision of Pulmonary, Allergy & Critical Care Medicine, Department of Medicine, Stanford University School of Medicine, 300 Pasteur Drive, MC 5573, Stanford, CA, 94305, USA.
Stanford University · USStanford Medicine · US

Funding

Stanford TRANSFORM I2T ProgramR25AI147369 · NIAID · STANFORD UNIVERSITY · PI CHERTOW, GLENN MATTHEW, SINGH, UPINDER · 2019 to 2023
$1.8M
NIAID NIH HHS R25 AI147369
6 · The paper itself

Abstract

While fluoroquinolones, vancomycin, macrolides, and tetracyclines are generally safe antibiotics, they can induce both immediate and delayed hypersensitivity reactions (HSRs). Historically, less has been published on allergies to these antibiotics compared to beta lactams, but the prevalence of non-beta lactam HSRs is increasing. To fluoroquinolones, immediate HSRs are more common than delayed reactions. Both IgE and non-IgE mechanisms, such as the mast cell receptor Mas-related G protein-coupled receptor X2 (MRGPRX2), have been implicated in fluoroquinolone-induced anaphylaxis. Skin testing for fluoroquinolones is controversial, and the gold standard for diagnosis is a graded dose challenge. To vancomycin, the most common reaction is vancomycin infusion reaction (previously called "red man syndrome"), which is caused by infusion rate-dependent direct mast cell degranulation. Severity can range from flushing and pruritis to angioedema, bronchospasm, and hypotension that mimic type I HSRs. MRGPRX2 has been implicated in vancomycin infusion reactions. IgE-mediated HSRs to vancomycin are rare. Vancomycin skin testing yields high false positive rates. Thus, direct provocation challenge with slower infusion rate and/or antihistamine pre-treatment is preferred if symptoms are mild to moderate, and desensitization can be considered if symptoms are severe. To tetracyclines, non-IgE-mediated and delayed HSRs predominate with cutaneous reactions being the most common. There is no standardized skin testing for tetracyclines, and avoidance is generally recommended after a severe reaction because of the paucity of data for testing. Graded dose challenges and desensitizations can be considered for alternative or index tetracyclines if there are no alternatives. With macrolides, urticaria/angioedema is the most common immediate HSR, and rash is the most common delayed HSR. The predictive value for skin testing to macrolides is similarly poorly defined. In general, HSRs to fluroquinolones, vancomycin, macrolides, and tetracyclines are challenging to diagnose given the lack of validated skin testing and in vitro testing. Direct provocation challenge remains the gold standard for diagnosis, but the benefits of confirming an allergy may not outweigh the risk of a severe reaction. Skin testing, direct provocation challenge, and/or desensitization to the index non-beta lactam antibiotic or alternatives in its class may be reasonable approaches depending on the clinical context and patient preferences.

Indexed as

AngioedemaDrug HypersensitivityHypersensitivity, ImmediateAnti-Bacterial AgentsFluoroquinolonesHumansImmunoglobulin EMacrolidesNerve Tissue ProteinsReceptors, G-Protein-CoupledReceptors, NeuropeptideTetracyclinesVancomycinAnti-Bacterial AgentsFluoroquinolonesImmunoglobulin EMacrolidesMRGPRX2 protein, humanNerve Tissue ProteinsReceptors, G-Protein-CoupledReceptors, NeuropeptideTetracyclinesVancomycinDrug allergyDrug hypersensitivityFluoroquinolonesMacrolideTetracyclinesVancomycin

Identifiers

PMID35092578
PMCPMC9167562
OpenAlexW4221083876

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.